Prime time for g-protein-coupled receptor heteromers as therapeutic targets for cns disorders: The dopamine D1-D3 receptor heteromer

CNS and Neurological Disorders - Drug Targets

Volumn 9, Issue 5, 2010, Pages 596-600

  Ferré, Sergi ^a   Lluis, Carmen ^b   Lanciego, José Luis ^c   Franco, Rafael ^b,c  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Cns; G protein coupled receptors; Heteromer tailored drugs; Homo and hetero oligomers; Parkinson's disease; Receptor heteromer

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 3 RECEPTOR; G PROTEIN COUPLED RECEPTOR; LEVODOPA; MONOMER; OLIGOMER;

ARTICLE; BASAL GANGLION; CENTRAL NERVOUS SYSTEM DISEASE; DRUG TARGETING; DYSKINESIA; NONHUMAN; PARKINSON DISEASE; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION;

EID: 78649286943     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152710793361603     Document Type: Article

References (50)

1. Bouvier, M. Oligomerization of G-protein-coupled transmitter receptors. Nat. Rev. Neurosci., 2001, 2, 274-286.
2. Devi, L.A. Heterodimerization of G-protein-coupled receptors:pharmacology, signaling and trafficking. Trends Pharmacol. Sci., 2001, 22, 532-537.
3. Milligan, G. Oligomerisation of G-protein-coupled receptors. J. Cell Sci., 2001, 114, 1265-1271.
4. George, S.R.; O'Dowd, B.F.; Lee, S.P. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat. Rev. Drug Discov., 2002, 1, 808-820.
5. Agnati, L.F.; Ferré, S.; Lluis, C.; Franco, R.; Fuxe, K. Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol. Rev., 2003, 55, 509-550.
6. Prinster, S.C.; Hague, C.; Hall, R.A. Heterodimerization of G protein-coupled receptors: specificity and functional significance. Pharmacol. Rev., 2005, 57, 289-298.
7. Ferré, S.; Ciruela, F.; Woods, A.S.; Lluis, C.; Franco, R. Functional relevance of neurotransmitter receptor heteromers in the central nervous system. Trends Neurosci., 2007, 30, 440-446.
8. Ferré, S.; Baler, R.; Bouvier, M.; Caron, M.G.; Devi, L.A.; Durroux, T.; Fuxe, K.; George, S.R.; Javitch, J.A.; Lohse, M.J.; Mackie, K.; Milligan, G.; Pfleger, K.D.; Pin, J.P.; Volkow, N.D.; Waldhoer, M.; Woods, A.S.; Franco, R. Building a new conceptual framework for receptor heteromers. Nat. Chem. Biol., 2009, 5, 131-134.
9. George, S.R.; Fan, T.; Xie, Z.; Tse, R.; Tam, V.; Varghese, G.; O'Dowd, B.F. Oligomerization of mu and delta-opioid receptors. Generation of novel functional properties. J. Biol. Chem., 2000, 275, 26128-26135.
10. Rozenfeld, R.; Devi, L.A. Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mudelta opioid receptor heterodimers. FASEB J., 2007, 21, 2455-2465.
11. Missale, C.; Nash, S.R.; Robinson, S.W.; Jaber, M.; Caron, M.G. Dopamine receptors: from structure to function. Physiol. Rev., 1998, 78, 189-225.
12. Lee, S.P.; So, C.H.; Rashid, A.J.; Varghese, G.; Cheng, R.; Lança, A.J.; O'Dowd, B.F.; George, S.R. Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase C-mediated calcium signal. J. Biol. Chem., 2004, 279, 35671-35678.
13. Rashid, A.J.; So, C.H.; Kong, M.M.; Furtak, T.; El-Ghundi, M.; Cheng, R.; O'Dowd, B.F.; George, S.R. D1-D2 dopamine receptor heterooligomers with unique pharamacology are coupled to rapid activation of Gq/11 in the striatum. Proc. Natl. Acad. Sci. USA, 2007, 104, 654-659.
14. Marcellino, D.; Ferré, S.; Casadó, V.; Cortés, A.; Le Foll, B.; Mazzola, C.; Drago, F.; Saur, O.; Stark, H.; Soriano, A.; Barnes, C.; Goldberg, S.R.; Lluis, C.; Fuxe, K.; Franco, R. Identification of dopamine D1-D3 receptor heteromers: Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J. Biol. Chem., 2008, 283, 26016-26025.
15. Fiorentini, C.; Busi, C.; Gorruso, E.; Gotti, C.; Spano, P.; Missale, C. Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol. Pharmacol., 2008, 74, 59-69.
16. Ginés, S.; Hillion, J.; Torvinen, M.; Le Crom, S.; Casadó, V.; Canela, E.I.; Rondin, S.; Lew, J.Y.; Watson, S.; Zoli, M.; Agnati, L.F.; Verniera, P.; Lluis, C.; Ferré, S.; Fuxe, K.; Franco, R. Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proc. Natl. Acad. Sci. USA, 2000, 97, 8606-8611.
17. Hillion, J.; Canals, M.; Torvinen, M.; Casado, V.; Scott, R.; Terasmaa, A.; Hansson, A.; Watson, S.; Olah, M.E.; Mallol, J.; Canela, E.I.; Zoli, M.; Agnati, L.F.; Ibanez, C.F.; Lluis, C.; Franco, R.; Ferre, S.; Fuxe, K. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J. Biol. Chem., 2002, 277, 18091-18097.
18. Kearn, C.S.; Blake-Palmer, K.; Daniel, E.; Mackie, K.; Glass, M. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol. Pharmacol., 2005, 67, 1697-1704.
19. Marcellino, D.; Carriba, P.; Filip, M.; Borgkvist, A.; Frankowska, M.; Bellido, I.; Tanganelli, S.; Müller, C.E.; Fisone, G.; Lluis, C.; Agnati, L.F.; Franco, R.; Fuxe, K. Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology, 2008, 54, 815-823.
20. Rocheville, M.; Lange, D.C.; Kumar, U.; Patel, S.C.; Patel, R.C.; Patel, Y.C. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science, 2000, 288, 154-157.
21. Juhasz, J.R.; Hasbi, A.; Rashid, A.J.; So, C.H.; George, S.R.; O'Dowd, B.F. Mu-opioid receptor heterooligomer formation with the dopamine D1 receptor as directly visualized in living cells. Eur. J. Pharmacol., 2008, 581, 235-243.
22. Cabello, N.; Gandía, J.; Bertarelli, D.C.; Watanabe, M.; Lluís, C.; Franco, R.; Ferré, S.; Luján, R.; Ciruela, F. Metabotropic glutamate type 5, dopamine D2 and adenosine A2A receptors form higher order oligomers in living cells. J. Neurochem., 2009, 109, 1497-1507.
23. Ferrada, C.; Ferré, S.; Casadó, V.; Cortés, A.; Justinova, Z.; Barnes, C.; Canela, E.I.; Goldberg, S.R.; Leurs, R.; Lluis, C.; Franco, R. Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. Neuropharmacology, 2008, 55, 190-197.
24. Ferrada, C.; Moreno, E.; Casadó, V.; Bongers, G.; Cortés, A.; Mallol, J.; Canela, E.I.; Leurs, R.; Ferré, S.; Lluís, C.; Franco, R. Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors. Br. J. Pharmacol., 2009, 157, 64-75.
25. Jiang, H.; Betancourt, L.; Smith, R.G. Ghrelin amplifies dopamine signaling by cross talk involving formation of growth hormone secretagogue receptor/dopamine receptor subtype 1 heterodimers. Mol. Endocrinol., 2006, 20, 1772-1785.
26. Carriba, P.; Navarro, G.; Ciruela, F.; Ferré, S.; Casadó, V.; Agnati, L.; Cortés, A.; Mallol, J.; Fuxe, K.; Canela, E.I.; Lluís, C.; Franco, R. Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nat. Methods, 2008, 5, 727-733.
27. Ferré, S.; Ciruela, F.; Canals, M.; Marcellino, D.; Burgueno, J.; Casadó, V.; Hillion, J.; Torvinen, M.; Fanelli, F.; Benedetti, Pd.P.; Goldberg, S.R.; Bouvier, M.; Fuxe, K.; Agnati, L.F.; Lluis, C.; Franco, R.; Woods, A. Adenosine A2A-dopamine D2 receptor receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat. Disord., 2004, 10, 265-271.
28. Ferre, S.; von Euler, G.; Johansson, B.; Fredholm, B.B.; Fuxe, K. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci. USA, 1991, 88, 7238-7241.
29. Ferré, S.; Fuxe, K.; von Euler, G.; Johansson, B.; Fredholm, B.B. Adenosine-dopamine interactions in the brain. Neuroscience, 1992, 51, 501-512.
30. Jenner, P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin. Investig. Drugs, 2005, 14, 729-738.
31. Muller, C.E.; Ferré, S. Blocking Striatal Adenosine A2A Receptors: A New Strategy for Basal Ganglia Disorders. Recent Pat. CNS Drug Discov., 2007, 2, 1-21
32. Waldhoer, M.; Fong, J.; Jones, R.M.; Lunzer, M.M.; Sharma, S.K.; Kostenis, E.; Portoghese, P.S.; Whistler, J.L. A heterodimer selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc. Natl. Acad. Sci. USA, 2005, 102, 9050-9055.
33. Rozenfeld, R.; Abul-Husn, N.S.; Gomez, I.; Devi, L.A. An emerging role for the delta opioid receptor in the regulation of mu opioid receptor function. Sci. World J., 2007, 7, 64-73.
34. Daniels, D.J.; Lenard, N.R.; Etienne, C.L.; Law, P.Y.; Roerig, S.C.; Portoghese, P.S. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc. Natl. Acad. Sci. USA, 2005, 102, 19208-19213.
35. Soriano, A.; Ventura, R.; Molero, A.; Hoen, R.; Casadó, V.; Cortés, A.; Fanelli, F.; Albericio, F.; Lluís, C.; Franco, R.; Royo, M. Adenosine A2A receptor-antagonist/dopamine D2 receptor-agonist bivalent ligands as pharmacological tools to detect A2A-D2 receptor heteromers. J. Med. Chem., 2009, 52, 5590-5602.
36. Scherrer, G.; Imamachi, N.; Cao, Y.Q.; Contet, C.; Mennicken, F.; O'Donnell, D.; Kieffer, B.L.; Basbaum, A.I. Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell, 2009, 137, 1148-1159.
37. Scherrer, G.; Tryoen-Tóth, P.; Filliol, D.; Matifas, A.; Laustriat, D.; Cao, Y.Q.; Basbaum, A.I.; Dierich, A.; Vonesh, J.L.; GavériauxRuff, C.; Kieffer, B.L. Knockin mice expressing fluorescent delta opioid receptors uncover G protein-coupled receptor dynamics in vivo. Proc. Natl. Acad. Sci. USA, 2006, 103, 9691-9696.
38. Wang, H.B.; Guan, J.S.; Bao, L.; Zhang, X. Distinct subcellular distribution of delta-opioid receptor fused with various tags in PC12 cells. Neurochem. Res., 2008, 33, 2028-2034.
39. Décaillot, F.M.; Rozenfeld, R.; Gupta, A.; Devi, L.A. Cell surface targeting of mu-delta opioid receptor heterodimers by RTP4. Proc. Natl. Acad. Sci. USA, 2008, 105, 16045-16050.
40. Berthet, A.; Porras, G.; Doudnikoff, E.; Stark, H.; Cador, M.; Bezard, E.; Bloch, B. Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia. J. Neurosci., 2009, 29, 4829-4835.
41. Gerfen, C.R. Basal Ganglia. In: Paxinos, G., Ed. The Rat Nervous System. Elsevier Academic Press; Amsterdam, 2004, pp. 445-508.
42. Surmeier, D.J.; Song, W.J.; Yan, Z. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J. Neurosci., 1996, 16, 6579-6591.
43. Ferré, S.; Giménez-Llort, L.; Artigas, F.; Martínez, E. Motor activation in shortand long-term reserpinized mice: role of Nmethyl-D-aspartate, dopamine D1 and dopamine D2 receptors. Eur. J. Pharmacol., 1994, 255, 203-213
44. Bordet, R.; Ridray, S.; Carboni, S.; Diaz, J.; Sokoloff, P.; Schwartz, J.C. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. Natl. Acad. Sci. USA, 1997, 94, 3363-3367.
45. Bordet, R.; Ridray, S.; Schwartz, J.C.; Sokoloff, P. Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. Eur. J. Neurosci., 2000, 12, 2117-2123.
46. Aubert, I.; Guigoni, C.; Håkansson, K.; Li, Q.; Dovero, S.; Barthe, N.; Bioulac, B.H.; Gross, C.E.; Fisone, G.; Bloch, B.; Bezard, E. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann. Neurol., 2005, 57, 17-26.
47. Guigoni, C.; Aubert, I.; Li, Q.; Gurevich, V.V.; Benovic, J.L.; Ferry, S.; Mach, U.; Stark, H.; Leriche, L.; Håkansson, K.; Bioulac, B.H.; Gross, C.E.; Sokoloff, P.; Fisone, G.; Gurevich, E.V.; Bloch, B.; Bezard, E. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism Relat. Disord., 2005, 11, S25-S29.
48. Sánchez-Pernaute, R.; Jenkins, B.G.; Choi, J.K.; Iris Chen, YC; Isacson O. In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias. Neurobiol. Dis., 2007, 27, 220-227.
49. Bézard, E.; Ferry, S.; Mach, U.; Stark, H.; Leriche, L.; Boraud, T.; Gross, C.; Sokoloff, P. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat. Med., 2003, 9, 762-767.
50. Visanji, N.P.; Fox, S.H.; Johnston, T.; Reyes, G.; Millan, M.J.; Brotchie, J.M. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease. Neurobiol. Dis., 2009, 35, 184-192.